



[Go to Product page](#)

Datasheet for ABIN6942805
anti-Cytokeratin 8/18 antibody

Overview

Quantity:	100 µL
Target:	Cytokeratin 8/18
Reactivity:	Human, Mouse
Host:	Rabbit
Clonality:	Monoclonal
Conjugate:	This Cytokeratin 8/18 antibody is un-conjugated
Application:	Flow Cytometry (FACS), Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (IHC), Immunofluorescence (Cultured Cells) (IF (cc))

Product Details

Immunogen:	Full length protein
Clone:	8C12
Isotype:	IgG
Cross-Reactivity:	Human, Mouse
Purification:	Purified by Protein A.

Target Details

Target:	Cytokeratin 8/18
Alternative Name:	Cytokeratin 8+18 (Cytokeratin 8/18 Products)
Background:	Synonyms: KeRatin, type II cytoskeletal 8, CytokeRatin-8, KeRatin-8, Type-II keRatin Kb8,

Target Details

KeRatin, type I cytoskeletal 18, Cell proliferation-inducing gene 46 protein, CytokeRatin-18, KeRatin-18, CK-8, K8, KRT8, CYK8, CK-18, K18, KRT18, CYK18

Background: Cytokeratins comprise a diverse group of intermediate filament proteins (IFPs) that are expressed as pairs in both keratinized and non-keratinized epithelial tissue.

Cytokeratins play a critical role in differentiation and tissue specialization and function to maintain the overall structural integrity of epithelial cells. They have been found to be useful markers of tissue differentiation, which is directly applicable to the characterization of malignant tumors. Cytokeratin 8 expression is seen in epithelium and epithelium-derived tumors. The Cytokeratin 8 and 18 pair are normally expressed in simple epithelia, but not in stratified epithelial cells. Research indicates that squamous cell carcinomas derived from stratified epithelia show abnormal expression of Cytokeratin 8 and 18, although it is not known whether these proteins contribute to the malignant phenotype of the cells. Expression of Cytokeratin 8 and 18 in oral squamous cell carcinomas is an independent prognostic marker that indicates a poor prognosis. Cytokeratin 8 expression correlates with malignancy in leukoplakia and carcinomas of the head and neck, it is expressed in all non-small-cell lung cancers. Cytokeratin 8 has been shown to possess extracellular epitopes on tumor cells, which may represent valuable targets for therapy.

UniProt: [P05783](#), [P05787](#)

Application Details

Application Notes: WB 1:300-5000
FCM 1:20-100
IHC-P 1:200-400
IF(ICC) 1:50-200
IHC()

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 µg/µL

Buffer: Aqueous buffered solution containing 1xTBS (pH 7.4), 1 % BSA, 40 %Glycerol and 0.05 % Sodium Azide.

Preservative: ProClin

Handling

Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
Storage:	-20 °C
Storage Comment:	Store at -20°C for 12 months.
Expiry Date:	12 months